Sacubitril + valsartan

3 papers3 findings

PubChem 9811834 PubChem 60846 ChEBI 134714 ChEBI 9927

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 2 countries

Funder: Ministero dell’Istruzione, dell’Università e della Ricerca
2 of 3 findings with company ties

Humans2
Animals1

Outcomes

Cardiac fibrosis

downin rats1

1 study

Sacubitril + valsartan decreases cardiac fibrosis in rats.
“Both treatments attenuated cardiac fibrosis and inflammation by downregulating TGF-β1/SMAD3 signalling and pro-inflammatory cytokines (IL-6, TNF-α, NF-κB).”
Animalsmodel of dysmetabolic aging heart failureheart45 weeksfemales
Benefits of sacubitril/valsartan alone and in combination with dapagliflozin in a preclinical female model of cardiometabolic and age-related cardiac dysfunction
Cardiovascular diabetology21 Mar 2026

NT-proBNP

downin rats1

1 study

Sacubitril + valsartan decreases NT-proBNP in rats.
“Functional improvements were paralleled by reductions in plasma NT-proBNP and myocardial BNP.”
Animalsmodel of dysmetabolic aging heart failureheart45 weeksfemales
Benefits of sacubitril/valsartan alone and in combination with dapagliflozin in a preclinical female model of cardiometabolic and age-related cardiac dysfunction
Cardiovascular diabetology21 Mar 2026

Associations

Major adverse cardiovascular events

downin humans1OR 0.751

1 study

Sacubitril + valsartan lowers the risk of major adverse cardiovascular events in humans (OR 0.751, 95% CI 0.575–0.981).
“and reduced MACE (odds ratio 0.751; 95% confidence interval 0.575–0.981) at five years.”
Humanscardiac amyloidosis receiving tafamidis5 years
Use of Contemporary Cardiometabolic Therapies in Cardiac Amyloidosis Treated with Tafamidis: A Real-World Propensity-Matched Analysis
AHA Scientific Sessions 2025 abstract3 Nov 2025